BRAIN CANCER

Naxitamab combined with GM-CSF shows promising results in treating high-risk neuroblastoma, achieving high response rates and manageable safety profiles.

A phase 1 study reveals that sequential CR7-GD2 CAR T-cell therapy administration is better tolerated in pediatric CNS tumor patients than concurrent methods.

Tovorafenib shows promising long-term efficacy for pediatric low-grade glioma, with significant treatment-free intervals and manageable safety profile.

New findings from the TEM-GBM study reveal promising survival rates for patients with glioblastoma treated with the experimental gene therapy Temferon.

Eflornithine combined with lomustine shows promising survival benefits for patients with recurrent IDH-mutant grade 3 astrocytoma in recent trials.

The FDA approves selumetinib for adults with neurofibromatosis type 1, offering new hope for treating inoperable plexiform neurofibromas.

Tinostamustine receives FDA orphan drug designation, promising new hope for glioblastoma treatment with innovative dual-action mechanism.

Vorasidenib shows significant long-term benefits for IDH-mutant glioma patients, enhancing survival and delaying treatment needs post-surgery.

Exosome-based therapy for glioblastoma receives FDA orphan drug designation, promising targeted treatment and improved delivery methods for cancer care.

The FDA fast tracks MT-125, a promising new treatment for glioblastoma, enhancing patient care and expediting drug development.

A clinical study highlights the safety and feasibility of ClearPoint Prism Neuro Laser Therapy for treating brain tumors, showcasing innovative minimally invasive techniques.

FDA grants orphan drug designation to cintredekin besudotox, offering new hope for glioblastoma treatment with targeted delivery methods.

FDA designates AMXT 1501 and DFMO as an orphan drug for neuroblastoma, aiming to enhance treatment outcomes for pediatric patients.

Dordaviprone gains NCCN approval as a promising treatment for recurrent H3 K27M-mutant diffuse glioma, addressing urgent patient needs.

The FDA approves selumetinib for young patients with neurofibromatosis type 1, offering hope for effective treatment of inoperable tumors.

FDA grants orphan drug designation to BA-101, a promising treatment for glioblastoma, aiming to improve outcomes in this challenging cancer.

Lantern Pharma advances pediatric CNS cancer treatment with FDA guidance on LP-184 trial, targeting rare tumors and enhancing therapy with spironolactone.

In a pilot study, a novel regimen showed 100% disease control in 5 patients with recurrent GBM, with 2 achieving near complete response.

Dordaviprone received accelerated FDA approval for H3 K27M-mutant diffuse midline glioma, an aggressive brain tumor, making it the first approved systemic therapy for this rare disease.

A new FDA-approved trial explores innovative treatments for recurrent glioblastoma, offering hope for patients facing this aggressive brain cancer.

FDA accelerates approval of dordaviprone, the first targeted therapy for aggressive diffuse midline glioma, offering hope for patients with H3 K27M mutation.

Hemispherian's GLIX1 gains FDA approval for glioblastoma trials, promising a novel therapy targeting DNA repair in tumor cells.

Patritumab deruxtecan shows promising survival rates and manageable safety in treating leptomeningeal metastatic disease, offering hope for patients with limited options.

Researchers explore glioblastoma's genetic complexity using innovative spatial profiling, aiming to enhance treatment strategies and understand tumor resistance.

The FDA designates SH-110 as an orphan drug, offering a safer oral treatment option for glioma patients with swallowing difficulties.